RxDoctor Payments DataLook up a doctor →

Ali Haider, MD

Interventional Cardiology · Astoria, NYNPI 1962665265

Payments from drug & device makers

$491,962in general payments, 2019–2025

Across 1,155 payments — averaging $425.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$260K
  • AstraZeneca$66K
  • Amgen$43K
  • Shockwave Medical, Inc$39K
  • Medtronic$32K
  • GSK$16K
  • plus $36K from 47 others
$4,781in research payments, 2019–2025

Across 1 payment — averaging $4781.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$5K

What the payments were for

  • Consulting fees$42,3289%
  • Speaking & faculty fees$338,65969%
  • Travel & lodging$66,79614%
  • Food & beverage$43,5919%
  • Education$1590%
  • Other$4290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$491,962 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$127,407
Medicare patients
204
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan41$50,453
JardianceEmpagliflozin45$44,011
BrilintaTicagrelor40$26,159
XareltoRivaroxaban40$24,336
FarxigaDapagliflozin Propanediol24$16,923
EliquisApixaban13$14,375
Repatha SureclickEvolocumab20$11,641
Repatha SyringeEvolocumab13$8,015
Praluent PenAlirocumab12$5,918
VascepaIcosapent Ethyl17$4,950
Atorvastatin Calcium128$1,350
Metoprolol Succinate82$1,177
Rosuvastatin Calcium43$873
Ezetimibe32$493
Valsartan14$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$924$50,45341 claims
Boehringer IngelheimJardiance$457$44,01145 claims
AstraZenecaBrilinta, Farxiga$66,369$43,08264 claims
Johnson & JohnsonXarelto$260,049$24,33640 claims
PfizerEliquis$172$14,37513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →